Review: Theca cells as active participants in ovarian aging
This review argues that theca cells, the follicle's main androgen-producing cells, actively contribute to ovarian aging through decline, steroidogenic impairment and senescence-related inflammation, and proposes them as targets for biomarkers and interventions. [1]
Automatic summary · not editorially reviewed
The key findings
In the two-cell, two-gonadotropin model, theca cells supply androgen precursors that granulosa cells convert to estradiol, so theca dysfunction impairs estrogen production regardless of granulosa competence. [1]
Single-cell transcriptomic analyses reportedly show age-dependent upregulation of senescence pathways and downregulation of FOXP1 in theca cells during ovarian aging. [1]
The review reports that exosomes, senolytics, mitochondria-targeted interventions and Wnt/β-catenin modulation restored theca cell function in preclinical models, and proposes theca-specific biomarkers and interventions for future research. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Theca cells of the ovarian follicle in the context of ovarian aging, with reference to related clinical conditions
- Summary based on
- Study abstract
- Original publication
- July 20, 2026
Theca cells in the two-cell model
The review states that ovarian aging has been attributed disproportionately to oocyte and granulosa cell decline, while theca cells were underappreciated. In the classical two-cell, two-gonadotropin model, theca cells supply androgen precursors that granulosa cells convert to estradiol. The authors argue that theca cell dysfunction therefore impairs estrogen production regardless of granulosa cell competence.
Supporting source [1]
Senescence, mitochondria and signaling in aging theca cells
According to the review, theca cells during ovarian aging show quantitative decline, transcriptional reprogramming and progressive steroidogenic impairment. Single-cell transcriptomic analyses reportedly show age-dependent upregulation of senescence pathways, including CDKN1A, NF-κB and SASP-associated factors, and downregulation of FOXP1, which normally suppresses senescence via CDKN1A repression. Senescent theca-interstitial cells are said to release CCL5, TNF-α, IL-1β and IL-6, which suppress steroidogenic genes, induce granulosa cell apoptosis and promote fibrosis. Mitochondrial dysfunction via aberrant GSK3β activation and dysregulation of the PTEN/PI3K/Akt/FOXO1 axis are also described.
Supporting source [1]
Clinical links and preclinical intervention proposals
The review links theca cell dysfunction to premature ovarian insufficiency, diminished ovarian reserve and polycystic ovary syndrome. It reports that emerging strategies – mesenchymal stem cell-derived exosomes, senolytics, mitochondria-targeted interventions and Wnt/β-catenin pathway modulation – restored theca cell function in preclinical models. The authors propose theca-specific biomarkers and targeted interventions as priorities for future translational research. These are proposals and preclinical findings, not established human treatments.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The transcriptomic, mechanistic and intervention findings are summarized by the authors, and the therapeutic strategies are described as effective only in preclinical models, not in humans.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Wu H, Zhang Z, Huang Q, Liu B, Liu L. · europepmc.org · July 20, 2026